Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

An mRNA meet-up
September 2019
SHARING OPTIONS:

TÜBINGEN, Germany & BOSTON—A new collaborative research agreement is underway between CureVac AG and Yale University to research and develop mRNA-based pulmonary therapeutic candidates. Per the agreement, the Yale team will undertake discovery research on targets related to pulmonary diseases and present resulting candidates to CureVac for preclinical and clinical development. CureVac will fund all discovery research and retains an option to acquire rights regarding the candidates.
 
“mRNA therapeutics are at the forefront of drug development, and CureVac is a leader in the field. We are very excited about the opportunity to merge our expertise in genomics of lung disease with CureVac’s expertise in mRNA therapeutic development to develop novel therapeutics for lung disease. We look forward to a fruitful collaboration,” said Dr. Geoff Chupp, leader of the Yale University team.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.